Akoya Biosciences (NASDAQ:AKYA) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.29) by 34.48 percent. The company reported quarterly sales of $18.350 million which missed the analyst consensus estimate of $24.281 million by 24.43 percent. This is a 14.29 percent decrease over sales of $21.410 million the same period last year.
Akoya Biosciences Q1 2024 Adj EPS $(0.39) Misses $(0.29) Estimate, Sales $18.350M Miss $24.281M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.